Compass Therapeutics (NASDAQ:CMPX) Releases Quarterly Earnings Results, Hits Expectations

Compass Therapeutics (NASDAQ:CMPX) released its earnings results on Monday. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12), Zacks reports.

Compass Therapeutics Trading Up 2.2%

NASDAQ CMPX opened at $1.82 on Monday. The company’s fifty day simple moving average is $2.00 and its 200-day simple moving average is $2.10. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08. The stock has a market cap of $251.68 million, a P/E ratio of -4.92 and a beta of 1.40.

Insiders Place Their Bets

In related news, insider Jonathan Anderman purchased 20,000 shares of the business’s stock in a transaction that occurred on Monday, April 7th. The shares were purchased at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now directly owns 21,000 shares of the company’s stock, valued at approximately $32,340. The trade was a 2,000.00% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of the company’s stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. 28.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

CMPX has been the topic of a number of research analyst reports. Wedbush reiterated an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 1st. Jefferies Financial Group lifted their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, February 10th. Piper Sandler assumed coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price objective on the stock. Guggenheim reduced their price target on shares of Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 1st. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Compass Therapeutics has a consensus rating of “Buy” and an average price target of $13.13.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.